Ladenburg analyst Kevin DeGeeter says recent selloff in Mesoblast following the secondary offering is unwarranted. The analyst recommends investors revisit the name ahead of the Phase II rheumatoid arthritis data. He reiterates a Buy rating on Mesoblast.
Mesoblast recent selloff unwarranted
-
- There are more pages in this discussion • 8 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.018(1.61%) |
Mkt cap ! $1.235B | |||
| Open | High | Low | Value | Volume |
| $1.10 | $1.10 | $1.06 | $2.666M | 2.491M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 16 | 41406 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.08 | 70313 | 32 |
View Market Depth
| Last trade - 13.30pm 20/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |